Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liver disease in hepatitis C virus carriers identified at blood donation and their outcomes with or without interferon treatment: Study on 1019 carriers followed for 5-10 years.
Mizui M, Tanaka J, Katayama K, Nakanishi T, Obayashi M, Aimitsu S, Yoshida T, Inoue J, Yokoyama T, Tsuji K, Arataki K, Yamaguchi S, Miura T, Kitamoto M, Takezaki E, Orimen S, Sakata T, Kamada K, Maruhashi A, Tamura T, Nakamura T, Ishida K, Teramen K, Miyakawa Y, Yoshizawa H. Mizui M, et al. Among authors: kitamoto m. Hepatol Res. 2007 Dec;37(12):994-1001. doi: 10.1111/j.1872-034X.2007.00157.x. Epub 2007 Jul 11. Hepatol Res. 2007. PMID: 17627620
Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.
Kawaoka T, Kawakami Y, Tsuji K, Ito H, Kitamoto M, Aimitsu S, Kawakami H, Jeong SC, Imamura M, Aikata H, Takahashi S, Chayama K. Kawaoka T, et al. Among authors: kitamoto m. J Gastroenterol Hepatol. 2009 Mar;24(3):366-71. doi: 10.1111/j.1440-1746.2008.05650.x. Epub 2008 Nov 20. J Gastroenterol Hepatol. 2009. PMID: 19032459 Clinical Trial.
Predicting the response to 48-week combination therapy with peginterferon alpha-2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype 1b hepatitis C patients.
Tsuji K, Kawakami Y, Aimitsu S, Kohno H, Aisaka Y, Kimura S, Nagata S, Ohgoshi H, Kitamoto M, Hidaka T, Kawakami H, Nakanishi T, Chayama K. Tsuji K, et al. Among authors: kitamoto m. Hepatol Res. 2009 Jun;39(6):531-8. doi: 10.1111/j.1872-034X.2009.00488.x. Epub 2009 Feb 25. Hepatol Res. 2009. PMID: 19254346
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.
Takaki S, Kawakami Y, Imamura M, Aikata H, Takahashi S, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Nakanishi T, Kitamoto M, Moriya T, Satoh K, Chayama K. Takaki S, et al. Among authors: kitamoto m. Intervirology. 2007;50(6):439-46. doi: 10.1159/000114718. Epub 2008 Feb 4. Intervirology. 2007. PMID: 18253048 Clinical Trial.
Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy.
Jeong S, Kawakami Y, Kitamoto M, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Uka K, Takaki S, Kodama H, Waki K, Imamura M, Aikata H, Takahashi S, Chayama K. Jeong S, et al. Among authors: kitamoto m. J Gastroenterol Hepatol. 2008 Apr;23(4):541-5. doi: 10.1111/j.1440-1746.2008.05356.x. J Gastroenterol Hepatol. 2008. PMID: 18397484 Clinical Trial.
Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems.
Kawaoka T, Aikata H, Takaki S, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Kamada K, Kitamoto M, Nakanishi T, Ishikawa M, Hieda M, Kakizawa H, Tanaka J, Chayama K. Kawaoka T, et al. Among authors: kitamoto m. Hepatol Res. 2010 Nov;40(11):1082-91. doi: 10.1111/j.1872-034X.2010.00714.x. Epub 2010 Sep 28. Hepatol Res. 2010. PMID: 20880059
Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
Yokoyama S, Kawakami Y, Imamura M, Hayes CN, Kohno H, Kohno H, Tsuji K, Aisaka Y, Kira S, Yamashina K, Nonaka M, Takahashi S, Moriya T, Kitamoto M, Aimitsu S, Nakanishi T, Kawakami H, Chayama K. Yokoyama S, et al. Among authors: kitamoto m. J Gastroenterol Hepatol. 2015 Feb;30(2):337-44. doi: 10.1111/jgh.12706. J Gastroenterol Hepatol. 2015. PMID: 25091289
77 results